Department of Dairy Science and Food Technology, Institute of Agricultural Sciences, Banaras Hindu University, Varanasi 221005, India; Department of Food Processing Technology, Karunya Institute of Technology and Sciences, Coimbatore 641114, India.
Department of Dairy Science and Food Technology, Institute of Agricultural Sciences, Banaras Hindu University, Varanasi 221005, India.
Int J Biol Macromol. 2024 Oct;277(Pt 1):134201. doi: 10.1016/j.ijbiomac.2024.134201. Epub 2024 Jul 26.
In the modern era, nanomedicine has developed novel drug-delivery strategies to improve chemotherapy. Nanotechnological-based treatment approaches for cancer through targeted tumour drug delivery and stimulus-responsive tumour microenvironment have gained tremendous success in oncology. The application of building block materials of these nanomedicines plays a vital role in cancer remediation. Despite successful application in various medical treatments, nanocarriers' lack of biodegradability and biocompatibility makes their use in a clinical context difficult. In addition, the preparation of current drug delivery systems is a major constraint. The current cancer treatment methods aim to destroy diseased tissue, frequently with the use of radiation and chemotherapy. These treatment options are accompanied by a significant level of toxicity, which has excellent potential to further medical issues in the afflicted patient. Polyhydroxyalkanoate (PHA) polymers are biodegradable and biocompatible polyesters that can potentially be used as nanoparticular delivery systems for cancer treatment. Previously, PHA has shown tremendous application as a packaging material in the food and pharma industry. PHA-based nanocarriers are an effective drug delivery system because of their non-immunogenicity, regulated drug release, high drug loading capacity, and targeted drug delivery. This review focuses on creating and using PHA-based nanocarriers in cancer treatment. Despite its many benefits, PHA-based nanocarriers have yet to progress to clinical trials for drug delivery applications due to several issues, including the polymers' hydrophobic nature and high production costs. This review examines these challenges along with existing alternatives.
在现代，纳米医学已经开发出了新的药物输送策略来改进化疗。基于纳米技术的癌症治疗方法通过靶向肿瘤药物输送和对肿瘤微环境的刺激响应，在肿瘤学领域取得了巨大的成功。这些纳米药物的构建块材料的应用在癌症修复中起着至关重要的作用。尽管在各种医疗应用中取得了成功，但纳米载体缺乏生物降解性和生物相容性，使得它们在临床环境中的应用变得困难。此外，当前药物输送系统的制备也是一个主要的限制因素。目前的癌症治疗方法旨在破坏病变组织，通常使用放射疗法和化学疗法。这些治疗选择伴随着相当程度的毒性，这对患者的健康状况有进一步恶化的巨大风险。聚羟基烷酸酯 (PHA) 聚合物是可生物降解和生物相容的聚酯，可作为癌症治疗的纳米载体。以前，PHA 已作为食品和制药行业的包装材料得到了广泛应用。基于 PHA 的纳米载体是一种有效的药物输送系统，因为它们具有非免疫原性、可调节的药物释放、高载药能力和靶向药物输送。本综述重点介绍了 PHA 基纳米载体在癌症治疗中的应用。尽管 PHA 基纳米载体具有许多优点，但由于聚合物的疏水性和高生产成本等问题，它们尚未进展到药物输送应用的临床试验阶段。本综述探讨了这些挑战以及现有的替代方案。
